FierceBiotech 26. Jan. 2026 'Things are looking up': British biotechs consider going public after yearslong IPO drought
FierceBiotech 23. Jan. 2026 Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials
FierceBiotech 23. Jan. 2026 Abbott shares sag as global diagnostic, nutrition business sales declines drag on earnings
FierceBiotech 23. Jan. 2026 J. Craig Venter launches genomics startup designed to boost diagnostic insights
FierceBiotech 23. Jan. 2026 Sanofi plans global filings for key eczema prospect despite mixed phase 3 readout
FierceBiotech 22. Jan. 2026 Corcept racks up phase 3 cancer win to bounce back from FDA Cushing's rejection
FierceBiotech 22. Jan. 2026 Corxel secures $287M series D to fund phase 2/3 obesity studies of oral GLP-1 drug
FierceBiotech 22. Jan. 2026 Hoth strikes back against cancer drug skin toxicities, but share price stays frozen
FierceBiotech 21. Jan. 2026 Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ
FierceBiotech 21. Jan. 2026 FDA outlines draft policy on MRD, complete response for accelerated approvals in multiple myeloma
FierceBiotech 21. Jan. 2026 IO mulls more layoffs months after halving head count in wake of cancer vaccine setback
FierceBiotech 21. Jan. 2026 Touching base: Beam CEO on gene editing biotech's 'big push' for in vivo delivery
FierceBiotech 21. Jan. 2026 Novo Nordisk offloads diabetes assets to Aspect amid cell therapy retreat